Infliximab en el tratamiento de la enfermedad de Crohn. Estudio preliminar
Author | dc.contributor.author | Gellona V., José | |
Author | dc.contributor.author | Zarraonandia A., Antón | es_CL |
Author | dc.contributor.author | Zúñiga D., Alvaro | es_CL |
Author | dc.contributor.author | Palma C., Renato | es_CL |
Author | dc.contributor.author | Contreras P., Jaime | es_CL |
Author | dc.contributor.author | Silva Ch., Jaime | es_CL |
Author | dc.contributor.author | González D., Róbinson | es_CL |
Author | dc.contributor.author | Quintana V., Carlos | es_CL |
Admission date | dc.date.accessioned | 2008-11-28T15:47:32Z | |
Available date | dc.date.available | 2008-11-28T15:47:32Z | |
Publication date | dc.date.issued | 2006 | |
Cita de ítem | dc.identifier.citation | Rev Méd Chile 2006; 134: 320-325 | en |
Identifier | dc.identifier.uri | https://repositorio.uchile.cl/handle/2250/127582 | |
Abstract | dc.description.abstract | Background: Tumor necrosis factor alpha, interleukin 6 and 1 have a pathogenic role in Crohn’s disease. Infliximab, a monoclonal antibody against tumor necrosis factor, is useful in the treatment of Crohn’s disease, specially when the disease is active and associated to fistula formation. Aim: To assess the effectiveness of Infliximab in patients with Crohn’s disease. Material and methods: Twelve patients with Crohn’s disease (aged 16 to 63 years, 10 women) refractory to treatment with steroid, 5-aminosalicylic acid, antimicrobials and immunomodulatory drugs, were studied. A single intravenous 5 mg/kg dose Infliximab was administered. The Crohn’s disease activity index (CDAI) was measured before and one week after the administration of the drug. Results: CDAI before and after Infliximab administration was 357 ±62 and 138 ±122 score points, respectively (p <0.005). According to this score, five patients had a severe and seven a moderate disease flare. The disease remitted in 7 (58%) and a clinical response was observed in 75%. Conclusions: A single dose of Infliximab was effective to induce remission of the disease in 75% of this selected group of patients with Crohn’s disease. | en |
Lenguage | dc.language.iso | es | en |
Keywords | dc.subject | Antibodies, monoclonal | en |
Título | dc.title | Infliximab en el tratamiento de la enfermedad de Crohn. Estudio preliminar | en |
Title in another language | dc.title.alternative | Infliximab in the treatment of patients with Crohn’s disease. Preliminary report | en |
Document type | dc.type | Artículo de revista |
Files in this item
This item appears in the following Collection(s)
-
Artículos de revistas
Artículos de revistas